A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.

[1]  P. Ström,et al.  Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. , 2018, European urology.

[2]  Martin Eklund,et al.  The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. , 2018, European urology.

[3]  Baris Turkbey,et al.  A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification , 2018, JAMA oncology.

[4]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[5]  A. Partin,et al.  Prostate Health Index density improves detection of clinically significant prostate cancer , 2017, BJU international.

[6]  P. Ström,et al.  Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. , 2017, European urology focus.

[7]  D. Moses,et al.  A multiparametric magnetic resonance imaging‐based risk model to determine the risk of significant prostate cancer prior to biopsy , 2017, BJU international.

[8]  M. Roethke,et al.  Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. , 2017, European urology.

[9]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study , 2017, The Lancet.

[10]  F. Bladou,et al.  Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. , 2016, Urologic oncology.

[11]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[12]  P. Scardino,et al.  Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study , 2015, Journal of the National Cancer Institute.

[13]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[14]  Maarten de Rooij,et al.  Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. , 2014, European urology.

[15]  F. Schröder,et al.  Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. , 2014, European urology.

[16]  S. Vowler,et al.  Identification of pathologically insignificant prostate cancer is not accurate in unscreened men , 2014, British Journal of Cancer.

[17]  P. Stattin,et al.  Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence , 2014, Journal of the National Cancer Institute.

[18]  Frederico Branco,et al.  Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. , 2010, European urology.

[19]  Andrew J Vickers,et al.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.

[20]  Dante diTommaso,et al.  Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.

[21]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[22]  Katarzyna J Macura,et al.  Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. , 2016, European urology.

[23]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.